Drug Discovery World · Mar 2025
Summarizes the company’s GLP-1 sex-differences research and quotes CEO David Tingley on more personalized therapy design.
Combination therapeutics for the world's toughest diseases
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Olio Labs is a South San Francisco biotech company building AI/ML-driven combination therapeutics. Its core platform, the Combination Design Engine (CoDE), aims to identify multi-drug combinations that improve efficacy and reduce side effects, with public work focused on obesity and GLP-1 response differences.
Primary product
Combination Design Engine (CoDE) for AI-driven combination therapeutics
Founded
2023
Headquarters
South San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
AI drug discovery / combination therapeutics
Offices
South San Francisco, California, United States (HQ)
San Francisco, California, United States
Business model
AI-driven therapeutic design platform
biotechnology R&D
drug discovery / therapeutics development
Funding
People & investors
Leadership
CEO & Co-Founder
Co-Founder & CTO
Gina Williams
Senior Research Scientist
Tim Krausz
Director of Engineering
Irene Grossrubatscher
Head of R&D
Kyle Rodgers
Mechanical Engineer
Evelyn Jaime
Laboratory Ops & QA Manager
Henry Ynion
Laboratory Technician
Work & culture
Public job postings describe a small, high-performance team built on technical excellence, trust, and relentless curiosity.
Compensation
A public Bay Area job posting listed a Laboratory Operations & Vivarium Manager base salary of $100,000-$160,000, indicating transparent market-rate compensation for at least some roles.
Benefits
Competitive health benefits
Dental benefits
Vision benefits
401(k)
Product & market
Pricing
Not publicly disclosed
Differentiators
- —Combination Design Engine for multi-drug design
- —Focus on thousands of interacting proteins rather than single-target design
- —Whole-body systems approach to therapeutics
- —Public research emphasis on sex differences in GLP-1 response
- —In vivo phenomic workflow to test combinations
Technology
AI
machine learning
Python
SolidWorks
Git
Airtable
custom ML models
in vivo phenomic assays
Customers
Mid-to-large pharmaceutical companies
Research collaborators
Patients with obesity/metabolic disease
Competitors
Owkin
Zephyr AI
AMPLY Discovery
Iambic
Nabla Bio
Nimbus Therapeutics
Schrödinger
Evozyne
Scale & contact
Estimated revenue
Third-party estimates conflict: about $1.4M/year to about $8.4M/year.
Latest news
FinSMEs · Mar 2025
Reports a $4.5M round led by Boom Capital and Overwater Ventures, with participation from Pioneer Fund, SciFounders, Scrum Ventures, Y Combinator (S23), and ZAKA.
PR Newswire · Mar 2025
Official press release for Olio Labs' study on GLP-1 side effects and sex differences, including its CoDE platform and investor backing.
Chain Drug Review · Mar 2025
Covers the study’s findings on higher nausea/vomiting rates in women and the potential for menstrual-cycle-based dosing.
Jobs and careers at Olio Labs
0 jobs at Olio Labs
No open positions
Check back later for new openings